

# PROGRAMME SUMMARY

Date Time	3 <sup>rd</sup> August 2018 (Friday)	4 <sup>th</sup> August 2018 (Saturday)		5 <sup>th</sup> August 2018 (Sunday)
0800 - 0830	<b>OPENING CEREMONY</b>	<b>PLENARY 4</b>		<b>Introduction</b>
				<b>Failed SVR To DAA - What Is Next?</b>
0830 - 0900	<b>PLENARY 1</b>	<b>SYMPOSIUM 4</b>		<b>Screening And Baseline Assessments</b>
0900 - 0930	<b>PLENARY 2</b>			
0930 - 1000	<b>PLENARY 3</b>	Tea Symposium		
1000 - 1030	Tea / Booth Visit / Poster Viewing	<b>SYMPOSIUM 5</b>		<b>Treatment Initiation And Monitoring</b>
1030 - 1100	<b>SYMPOSIUM 1</b>	<b>PLENARY 5</b>		Tea
1100 - 1130		<b>SYMPOSIUM 6</b>		<b>Post Treatment Management</b>
1130 - 1200	<b>Lunch Symposium</b>			<b>Case Discussion</b>
1200 - 1230				
1230 - 1300	<b>Poster Rounds</b>	<b>Lunch Symposium</b>		Lunch
1300 - 1330				
1330 - 1400				
1400 - 1430				<b>Dealing With Complications Of Liver Cirrhosis</b>
1430 - 1500	<b>SYMPOSIUM 2</b>	<b>SYMPOSIUM 7</b>	<b>SYMPOSIUM 8</b>	<b>Closing Remarks</b>
1500 - 1530	<b>SYMPOSIUM 3</b>			
1530 - 1600		Tea		
1600 - 1630				
1630 - 1700	<b>Case Discussion</b>			
1700 - 1730				
1730 - 1800	Tea			
1800 - 1830				
1830 - 1900				
1900 - 1930				
1930 - 2200	<b>Faculty Dinner</b> <i>(By Invitation Only)</i>			

# DAILY PROGRAMME

## 3<sup>rd</sup> August 2018 (Friday)

### Venue: Nexus 1

- 0800 - 0830 **OPENING CEREMONY**  
Welcome Address  
*Rosmawati Mohamed*  
President, APASL STC on HCV And Organising Chairperson  
Keynote Speech  
*Ying-Ru Lo*  
WHO Representative
- 0830 - 0900 **PLENARY 1**  
*Chairperson: Saeed Hamid*  
Global And Regional Progress In Viral Hepatitis - An Update By WHO  
*Linh-Vi N Le*  
WHO Regional Office for Western Pacific
- 0900 - 0930 **PLENARY 2 | Presidential Lecture**  
*Chairperson: Diana Payawal*  
Simplifying The HCV Treatment Landscape In 2018  
*Rosmawati Mohamed*  
President, APASL STC on HCV
- 0930 - 1000 **PLENARY 3**  
*Chairperson: Tan Soek Siam*  
WHO Guidelines For Testing, Diagnosis And Treatment Of Hepatitis C  
Virus Infection: Application And Feasibility In Asia-Pacific  
*Saeed Hamid*  
Aga Khan University, Pakistan
- 1000 - 1030 Tea / Booth Visit / Poster Viewing
- 1030 - 1125 **SYMPOSIUM 1 | Approach To Challenging HCV Cases**  
*Chairpersons: A Kadir Dokmeci / Oidov Baatarkhuu*
- 1030 - 1045 Identifying The Cirrhotics And Their Unique Management  
*Teerha Piratvisuth*  
Songklanagarind Hospital, Prince of Songkla University, Thailand
- 1045 - 1100 Co-Infection: Managing HCV In People Living With HIV/HBV  
*Gail Matthews*  
Kirby Institute, Australia
- 1100 - 1115 ESRD And Other Extrahepatic Manifestations  
*Diana Payawal*  
President, APASL
- 1115 - 1125 Q&A
- 1125 - 1225 **Lunch Symposium (ABBOTT)**  
HCV Core Antigen In Community Screening Strategies  
*Wang Jing-Houng*  
Kaohsiung Medical College, Taiwan

# DAILY PROGRAMME

## 3<sup>rd</sup> August 2018 (Friday)

Venue: Nexus 1

- 1225 - 1400 **Poster Rounds**  
*Tan Soek Siam, Teerha Piratvisuth, A Kadir Dokmeci*
- 1430 - 1520 **SYMPOSIUM 2 | The Road To Hepatitis C Elimination In Asia**  
*Chairpersons: Suresh Kumar / Linh-Vi N Le*
- 1430 - 1445 Using The Echo Model For Community Out-reach Programmes In Asia  
*Saeed Hamid*  
Aga Khan University, Pakistan
- 1445 - 1500 Screening Strategies - Targeted vs General  
*Yasmin Malik*  
University Malaya Medical Centre, Malaysia
- 1500 - 1520 Q&A
- 1520 - 1630 **SYMPOSIUM 3 | Asia Pacific HCV Experience - Sharing Pearls Of Wisdom**  
*Chairpersons: Aliza Mutalib / Sha'ari Ngadiman*
- 1520 - 1535 The Australian Experience: Lessons In HCV Eliminations  
*Gail Mathews*  
Kirby Institute, Australia
- 1535 - 1550 HCV Treatment In Mongolia  
*Oidov Baatarxhuu*  
Mongolian National University of Medical Sciences, Mongolia
- 1550 - 1605 DAA RX Of HCV In China In Real Life  
*George Lau*  
Humanity And Health Medical Group, Hong Kong SAR, China
- 1605 - 1620 The Burden Of HCV In Armenia, Gaps And Required Interventions  
*Hasmik Ghazinian*  
"Nork" Clinical Hospital of Infectious Diseases, Yerevan, Armenia
- 1620 - 1630 Q&A
- 1630 - 1730 **Case Discussions on HCV-HIV Co-Infection**  
*Panelists: Sharifah Faridah / Gail Mathews / James Koh / Tan Soek Siam*  
*Presenters:*  
*Ng Tiong Koi*  
Hospital Sungai Buloh, Malaysia  
*Ng Rong Xiang*  
University Malaya Medical Centre, Malaysia  
*Alfazita Amran*  
Hospital Sungai Buloh, Malaysia
- 1730 - 1745 Tea
- 1930 **Faculty Dinner (By Invitation Only)**

# DAILY PROGRAMME

## 4<sup>th</sup> August 2018 (Saturday)

Venue: Nexus 1

- 0800 - 0830 **PLENARY 4**  
*Chairperson: Yasmin Malik*  
Is B Like C - Will It Be Curable?  
*Lim Seng Gee*  
National University Hospital, Singapore
- 0830 - 0920 **SYMPOSIUM 4 | *Emerging Obstacles In HCV Management / Eliminations In Asia***  
*Chairperson: Muhammad Radzi*
- 0830 - 0845 Management Of DAA Failures  
*Teerha Piratvisuth*  
Songklanagarind Hospital, Prince of Songkla University, Thailand
- 0845 - 0900 Treating HCV In Decompensated Cirrhotics-The Difficulties And Benefits  
*Hasmik Ghazinian*  
“Nork” Clinical Hospital of Infectious Diseases, Yerevan, Armenia
- 0900 - 0915 Is Elimination Of HCV An Attainable Priority From An Economic Perspective?  
*Maznah Dahlui*  
University Malaya Medical Centre, Malaysia
- 0915 - 0920 Q&A
- 0920 - 1020 **Tea Symposium (Siemens)**  
A Dynamic Continuous Biomarker For Liver Fibrosis: The ELF Test  
*Richard Rumnong*  
Siemens Healthineers, India
- 1020 - 1110 **SYMPOSIUM 5 | *Hepatitis C And Other Concurrent Diseases***  
*Chairpersons: Haniza Omar / Oidov Baatarkhuu*
- 1020 - 1035 GT3 HCV With Concomitant Fatty Liver - Will Steatosis Go Away?  
*Chow Wan Cheng*  
Singapore General Hospital, Singapore
- 1035 - 1050 HCV Patients Also Needing Immunosuppressive Therapy - What Is Important?  
*Tawesak Tanwandee*  
Siriraj Hospital, Mahidol University, Thailand

# DAILY PROGRAMME

## 4<sup>th</sup> August 2018 (Saturday)

Venue: Nexus 1

- 1050 - 1105 HCV And Its Association With Hematological Conditions  
*A Kadir Dokmeci*  
Ankara University, Turkey
- 1105 - 1110 Q&A
- 1110 - 1140 **PLENARY 5**  
*Chairperson: A Kadir Dokmeci*  
APASL Mission: Viral Hepatitis Elimination And HCC Management  
*Masao Omata*  
University of Tokyo, Japan
- 1140 - 1300 **SYMPOSIUM 6 | *Finding The Missing Millions And Advances In Diagnostics***  
*Chairpersons / Panelists: Tanya Applegate / Tan Soek Siam / Yasmin Malik*
- 1140 - 1200 Simplifying HCV Diagnosis - What We Need To Achieve Global Elimination  
*Tanya Applegate*  
Kirby Institute, Australia
- 1200 - 1220 HCV Market Intelligence Report To Increase Diagnostic Coverage In LMICs  
*Francesco Marinucci*  
FIND, Geneva, Switzerland
- 1220 - 1230 Experiences From Pakistan - Considerations In Planning To Scale Up  
*Saeed Hamid*  
Aga Khan University, Pakistan
- 1230 - 1240 Solutions From Indonesia - Reaching Remote Communities  
*Rino A Gani*  
University of Indonesia, Indonesia
- 1240 - 1300 Q&A / Panel Discussion
- 1300 - 1400 **Lunch Symposium (MSD) | *Personalised HCV Therapy In The Era Of Elimination***  
  
Role Of Individualized Therapy In The Broader Perspective Of Hepatitis C Elimination  
*Rosmawati Mohamed*  
President, APASL STC on HCV  
  
Treatment Options For Hepatitis C: A Case Presentation  
*Alex Leow*  
University Malaya Medical Centre, Malaysia

# DAILY PROGRAMME

## 4<sup>th</sup> August 2018 (Saturday)

Venue: Nexus 1

1430 - 1620	<b>CONCURRENT SESSIONS</b>	
	<i>Venue: Spectrum</i>	
	<p><b>SYMPOSIUM 7   HCV and HCC: A Multidisciplinary Approach</b>  <i>Chairpersons: Alex Tang / B K Yoong</i></p>	<p><b>SYMPOSIUM 8   Impactful Advocacy</b>  <i>Chairpersons: Tee Hoi Poh / Suresh Kumar / Jean-Michel Piedagnel</i></p>
1430 - 1445	<p>HCV Therapy And HCC - Is There Increased Risk And Severity?  <i>Gregory Dore</i>            Kirby Institute, Australia</p>	<p>Champions! The Role Of Hepatologists In Hepatitis Eliminations  <i>Linh-Vi N Le</i>            WHO Regional Office for Western Pacific</p>
1445 - 1500	<p>An Update On The Surgical Management Of HCC  <i>B K Yoong</i>            University Malaya Medical Centre, Malaysia</p>	<p>Community Based Program - The Achievements And Challenges  <i>Lim Teck Onn</i>            Consultant in Health Research, Malaysia</p>
1500 - 1515	<p>Treatment For Early Stage HCC: Is Ablative Therapy As Good As Surgery?  <i>Norshazriman bin Sulaiman</i>            University Malaya Medical Centre, Malaysia</p>	<p>Breaking The Stigma And Barriers In Society  <i>Sharifah Faridah</i>            University Malaya Medical Centre, Malaysia</p>
1515 - 1530	<p>Treatment For Intermediate Stage HCC: How Do I Decide?  <i>Alex Tang</i>            Ramsay Sime Darby Health Care, Malaysia</p>	<p>1515 - 1525  <b>Q&amp;A</b></p>
1530 - 1540	<p><b>Q&amp;A</b></p>	<p>1525 - 1540            The Voice Of Hepatitis - My Experience And My Actions  <i>Alice Lee Chia Yee</i>            Hepatitis Support Group</p>
1540 - 1555	<p>Palliation In ESLD - Living Well, Dying Well  <i>Cindy Teoh</i>            Selayang Hospital, Malaysia</p>	<p><i>Yatie Jonet</i>            Women Who Use Drugs &amp; PLHCV, Malaysian AIDS Council</p>
1555 - 1620	<p><b>Q&amp;A</b></p>	<p>1540 - 1600            Treatment As Prevention - Engaging The Marginalised  <i>Gregory Dore</i>            Kirby Institute, Australia</p>
		<p>1600 - 1610  <b>Q&amp;A / Round Table Discussion</b></p>

1620 - 1640 Tea

# HCV MASTERCLASS: THE A TO Z FOR HCV TREATERS

5<sup>th</sup> August 2018 (Sunday)

Venue: Nexus 1

- 0800 - 0815 **Introduction**  
*Chairpersons: Rosaida Hj Md Said / Nazrila Hairizan*  
Hepatitis C - The Burden, Management Cascade And Goals  
*Muhammad Radzi Abu Hassan*  
Hospital Sultanah Bahiyah, Malaysia
- 0815 - 0835 **Failed SVR To DAA - What Is Next?**  
*Diana Payawal*  
President, APASL
- 0835 - 0950 **Screening And Baseline Assessments**  
*Chairpersons: Rosaida Hj Md Said / Nazrila Hairizan*
- 0835 - 0850 **Screening For Hepatitis C - How And What I Do?**  
*Gregory Dore*  
Kirby Institute, Australia
- 0850 - 0905 **Baseline Pre-Treatment Assessments:**  
- History, Examination & Tests - What Do I Do?  
*Tan Soek Siam*  
Scientific Chairperson, APASL STC on HCV
- 0905 - 0925 - Non-Invasive Tests For Liver Fibrosis - Their Practical Use And Pitfalls?  
*Chan Wah Kheong*  
University Malaya Medical Centre, Malaysia
- 0925 - 0945 - How Do I Tackle Drug - Drug Interactions And Ensure Adherence?  
*Rino A Gani*  
University of Indonesia, Indonesia
- 0945 - 0950 **Q&A**
- 0950 - 1035 **Treatment Initiation And Monitoring**  
*Chairpersons: Tee Hoi Poh / Oidov Baatarkhuu*
- 0950 - 1010 **The Treatments Available In 2018**  
- How Do I Select The Right One For My Patient?  
*Lim Seng Gee*  
National University Hospital, Singapore
- 1010 - 1030 **On Treatment Monitoring And Optimizing Outcome**  
- Best And Innovative Approach  
*Tawesak Tanwandee*  
Siriraj Hospital, Mahidol University, Thailand
- 1030 - 1035 **Q&A**

# HCV MASTERCLASS: THE A TO Z FOR HCV TREATERS

5<sup>th</sup> August 2018 (Sunday)

Venue: Nexus 1

1035 - 1100 Tea

1100 - 1130 **Post Treatment Management**

*Chairpersons: Tee Hoi Poh / Oidov Baatarkhuu*

1100 - 1120 **After SVR - To Discharge Or Not To Discharge?**

*Chow Wan Cheng*

Singapore General Hospital, Singapore

1120 - 1130 Q&A

1130 - 1240 **Case Discussion**

*Panelists: A Kadir Dokmeci / Chow Wan Cheng / Diana Payawal*

Case Discussions

*Chan Wah Keong*

University Malaya Medical Centre, Malaysia

1240 - 1400 Lunch

1400 - 1510 **Dealing With Complications Of Liver Cirrhosis**

*Chairpersons: James Koh / Tee Hoi Poh*

1400 - 1420 **An Update On Management Of Ascites**

*Alex Leow*

University Malaya Medical Centre, Malaysia

1420 - 1440 **An Update On Management Of Variceal Bleeding**

*Tee Hoi Poh*

KPJ Pahang Specialist Hospital, Malaysia

1440 - 1510 Q&A

1510 - 1530 **Closing Remarks**